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Abstract
The objective of this study was to determine whether the different time-course
characteristics of a1-adrenoceptor-mediated contraction in arteries can be
related to the subtypes involved. Contractile responses to noradrenaline (NA)
were compared with inositol phosphate accumulation and extracellular signal-
regulated kinase (ERK)1/2 phosphorylation after a1-agonist stimuli in the same
vessels in the presence or absence of a1-antagonists in rat or in a1-subtype
knockout (KO) mice. Aorta, where a1D-AR is the main functional subtype, had
higher sensitivity to NA (in respect of inositol phosphate [IP], pERK1/2, and
contractile response) than tail artery, where the a1A-adrenoceptor subtype is
predominant. Furthermore, the contraction in aorta exhibited a slower decay
after agonist removal and this was consistent in all strains harboring a1D-
adrenoceptors (from rat, a1B-KO, and wild-type [WT] mice) but was not
observed in the absence of the a1D-adrenoceptor signal (a1D-adrenoceptor
blocked rat aorta or aorta from a1D-KO). IP formation paralleled a1-adrenocep-
tor-mediated contraction (agonist present or postagonist) in aorta and tail
artery. High sensitivity to agonist and persistence of response after agonist
removal is a property of a1D-adrenoceptors. Therefore, the preponderance of
this subtype in noninnervated conductance arteries such as aorta allows respon-
siveness to circulating catecholamines and prevents abrupt changes in vessel cal-
iber when the stimulus fluctuates. Conversely, in innervated distributing
arteries, high local concentrations of NA are required to activate a1A-adreno-
ceptors for a response that is rapid but short lived allowing fine adjustment of
the contractile tone by perivascular sympathetic nerves.
Abbreviations
AR, a1-adrenoceptors; CRC, Concentration–response curves; EDTA, ethylenedi-
aminetetraacetic acid; IP, inositol phosphate; KO, knockout; MAPK, mitogen-acti-
vated protein kinase; NA, noradrenaline; PBS, phosphate-buffered saline; PDZ,
PSD95/DlgA/Zo-1; PVDF, polyvinyldiene fluoride; WT, wild-type.
Introduction
The a1-adrenoceptors (ARs) are responsible for the con-
tractile response to catecholamines in blood vessels and,
classically, three different subtypes have been character-
ized, a1A, a1B, and a1D-ARs. The presence of mRNA or
receptor protein is not well correlated with contractile
function; in several examples, mRNA and protein for all
three a1-AR subtypes are expressed in a vessel, yet phar-
macological analysis shows that a single subtype is mainly
responsible for mediating contraction. There is, however,
some correlation between the subtype involved in mediat-
ing vascular contraction and the type of vessel. For exam-
ple, a1A-ARs mediate contraction of well-innervated
distributing arteries such as renal (Hrometz et al. 1999),
tail (Lachnit et al. 1997; Tanaka et al. 2004), and distal
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mesenteric and resistance arteries such as small mesenteric
branches (Philipp and Hein 2004; Martı et al. 2005;
Methven et al. 2009a). On the other hand the a1D-AR has
been shown to regulate the contraction of poorly inner-
vated conductance arteries such as the aorta, femoral,
iliac, carotid, pulmonary, and superior mesenteric artery
(Piascik et al. 1995; Hussain and Marshall 1997; Rudner
et al. 1999; Gisbert et al. 2000; Arevalo-Leon et al. 2003;
Martı et al. 2005; Methven et al. 2009b) and there is only
limited direct evidence that the a1B-AR is a mediator of
contractile function in blood vessels (Cavalli et al. 1997;
Daly et al. 2002; Tanoue et al. 2003; Cotecchia 2010;
Docherty 2010). Thus, vascular a1-AR subtypes may cor-
relate with the different functions of smooth muscle in
these different vascular types, that is, compliance of large
arteries (a1D) and redistribution of blood flow between
different organ systems (a1A) as we have previously dis-
cussed (Daly et al. 2002; Ziani et al. 2002).
In general, a1-ARs manifest different sensitivity to ag-
onists, the a1D-subtype being the most sensitive (Theroux
et al. 1996; Taguchi et al. 1998; Gisbert et al. 2000; Pia-
scik and Perez 2001; Daly et al. 2002). Once activated, the
three a1-AR subtypes interact with the Gq protein but
can also activate a variety of other signaling pathways
such as Gi and Go proteins or mitogen-activated protein
kinases (MAPKs) (Hawrylyshyn et al. 2004; Hein and
Michel 2007; Cotecchia 2010) that are less well explored
in native tissues. Nevertheless, there are marked differ-
ences in the ability of each subtype to generate intracellu-
lar second messengers (Garcıa-Sainz et al. 1999b; Zhong
and Minneman 1999; Keffel et al. 2000; Piascik and Perez
2001). The a1A-AR is most efficiently coupled to inositol
phosphate production, increases in cytosolic calcium con-
centrations, and MAPKs pathway, whereas the a1D-AR is
poorly coupled to intracellular signaling cascades (Schw-
inn et al. 1991; Theroux et al. 1996; Taguchi et al. 1998;
Zhong and Minneman 1999; Garcıa-Sainz and Villalobos-
Molina 2004; Hein and Michel 2007; Garcı´a-Cazarı´n
et al. 2008). This points to the possibility that potential
differences in their efficacy result in different functional
outcomes for each a1-AR subtype.
There are more observations that add complexity to
this scenario. As previous results obtained by our research
group indicate, native a1D-AR remains active after remov-
ing the agonist (Noguera and D’Ocon 1993; Noguera
et al. 1996; Gisbert et al. 2000, 2002, 2003b; Ziani et al.
2002) in vessels where this subtype play a functional role.
They act as “constitutively active” receptors which main-
tain an increased vascular tone for some time after the
adrenoceptor-mediated stimulus is removed (Ziani et al.
2002). This constitutive activity of a1D-ARs has also been
found in stably transfected rat fibroblasts and HEK293
cells where a a1D-mediated pERK1/2 signal was observed
in the absence of an adrenoceptor-mediated stimulus
(Garcıa-Sainz and Torres-Padilla 1999a; McCune et al.
2000; Chalothorn et al. 2002; Perez-Aso et al. 2013).
We propose that the characteristic behavior of the a1D-
subtype: higher sensitivity, sustained activity after removal
of the agonist, and its presence in the poorly innervated
conductance vessels, could determine a distinctive time-
course of the adrenoceptor-mediated contraction in these
vessels, and permit them to respond to the circulating
levels of catecholamines (rarely above 10 nmol/L) (Gold-
stein et al. 2003).
In the present work, we confirm this hypothesis by ana-
lyzing the characteristics of the response elicited by a1-ARs
in two different vessels, aorta, a territory where the a1D-AR
subtype plays the main functional role, and tail artery as a
vessel where the a1A-AR subtype is the main one responsible
of the adrenoceptor-mediated contractile response. Involve-
ment of subtypes was manipulated by the use of selective
antagonists in the rat and subtype knockouts in the mouse
(a1B-KO, a1D-KO, and a1B/D-KO). Signaling pathways were
investigated alongside contractility studies by analyzing
inositol phosphate accumulation and extracellular signal-
regulated kinase (ERK)1/2 phosphorylation after adreno-
ceptor stimulus in the same vessels.
Materials and Methods
Animals
Thoracic aorta and tail artery were obtained as previously
described (Gisbert et al. 2000) from male Wistar rats
(200–250 g) from colonies of wild-type (WT) and a1D-
KO mice, kindly supplied by Professor Gozoh Tsujimoto
(Department of Molecular Cell Pharmacology, National
Research Institute for Child Health and Development,
Tokyo), a1B-KO mice, kindly supplied by Professor Sus-
anna Cotecchia (Department de Pharmacologie et de
Toxicologie, Universite de Lausanne, Switzerland), and
a1B/D-KO mice generated by crossing these a1D-KO and
a1B-KO strains at University of Glasgow (see Methven
et al. 2009a). All protocols complied with European Com-
munity guidelines for experimental animals and were
approved by the Ethics Committee of the University of
Valencia.
Functional studies
Rings obtained from rat vessels and mouse aorta, were
denuded of endothelium by gentle rubbing and sus-
pended in an organ bath. Tension was recorded isometri-
cally according to the protocol previously described
(Martı et al. 2005). Arterial rings from the mouse tail
were mounted on an isometric wire myograph (J.P. Trad-
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ing, Aarhus, Denmark) according to the procedure previ-
ously described (Martinez-Rivelles et al. 2012). All vessels
were maintained in Krebs buffer, at 37°C and gassed with
95% O2 and 5% CO2.
An initial load of 9.81 mN was applied to each prep-
aration and maintained throughout a 75–90 minutes
equilibration period. The rings were stimulated with
noradrenaline (NA) (10 lmol/L in tail artery or
1 lmol/L in aorta) which produced a maximal contrac-
tion. The lack (<10%) of a relaxant response to acetyl-
choline (100 lmol/L) in these precontracted
preparations indicated the absence of a functional endo-
thelium. After 30 minutes washout, contractile responses
to NA were elicited according to different experimental
procedures:
(a) Concentration–response curves (CRC) to NA. This
experimental procedure was performed in each vessel by
addition of cumulative concentrations of NA (0.0001–
10 lmol/L) until a maximal response was obtained. From
these curves, pD2 and Emax were calculated using a nonlin-
ear regression plot (Graph Pad Software; San Diego, CA).
(b) Sustained contractile response to NA. The experi-
mental procedure was performed according to previous
studies (Noguera and D’Ocon 1993; Gisbert et al. 2000;
Ziani et al. 2002). A maximal contractile response to
NA (1 lmol/L in aorta, 10 lmol/L in tail artery) was
obtained in Ca2+-containing medium; this concentration
was maintained until a stable tone was reached and
then washed. In some experiments, BMY 7378 or 5-
methylurapidil were added 15 minutes prior to NA
addition. The washing procedure was carried out with
a total replacement of the bathing solution by three
repeated washes within the first 30 seconds and by two
other repeated washes every 5 minutes in all cases.
The tone was measured at different times during the
development of the contractile response and after
washing until total recovery of the basal tone. The
results were expressed as percentages of maximal con-
tractile responses.
(c) Increase in vascular tone after removal of the agonist.
Vessels were incubated in a Ca2+-free solution (contain-
ing 0.1 mmol/L ethylenediaminetetraacetic acid, EDTA)
for 20 minutes, which led to a small loss in tension
(<10–15%); then, vessels were exposed to NA (1 lmol/L
in aorta, 10 lmol/L in tail artery) twice, 10 minutes
each time, the tissues being carefully washed between
the two exposures, following the same procedure
described above. A spontaneous increase in vascular tone
was observed when the Ca2+-free solution was substi-
tuted by a Ca2+-containing medium. The effects of
prazosin, 5-methylurapidil, and BMY 7378 were assessed
on this spontaneous increase in tone. One micromolar
of each antagonist was added during incubation in
Ca2+-free medium, 10 minutes before addition of Ca2+-
containing solution and was maintained during the
Ca2+-loading period. Contraction was expressed in mN.
Accumulation of [3H]-inositol phosphates
The determination of the accumulation of inositol phos-
phates (IPs) has been previously described (Gisbert et al.
2003b). Briefly, rat tail arteries or thoracic aortas were cut
into rings, pooled, and submitted to different experimen-
tal procedures:
(a) Incubation for 30 minutes with increasing concen-
trations of NA (0.01 lmol/L–0.1 mmol/L) in the presence
of LiCl (10 mmol/L) in order to inhibit the metabolism
of inositol monophosphates.
(b) Incubation for 30 minutes with 1 lmol/L of prazo-
sin, 5-methylurapidil, or BMY 7378, in the presence of
LiCl (10 mmol/L) and in presence or absence of NA
(1 lmol/L in aorta, 10 lmol/L in tail artery).
(c) Incubation for 30 minutes with NA (1 lmol/L in
aorta, 10 lmol/L in tail artery) in Ca2+-free medium in
the absence of LiCl to avoid accumulation of inositol
phosphates, followed by removal of the agonist by careful
washing, and incubation for 30 minutes in Ca2+-contain-
ing medium in the presence of LiCl (10 mmol/L).
At the end of the functional experiments all vessels
were immediately frozen and processed as previously pub-
lished (Monto et al. 2012) to obtain total proteins.
Accumulation of [3H]-IPs was routinely calculated as
dpm of total [3H]-inositol labeled lipids/lg of protein in
each individual sample. CRC for NA-induced [3H]-IPs
accumulation were fitted by nonlinear regression plot
(Graph Pad Software; San Diego, CA) and the pEC50 and
Emax values were obtained.
Determination by immunoblotting of NA-
mediated ERK1/2 activation
Rings of rat aorta or tail artery were loaded in tubes con-
taining 5 mL of Krebs solution gassed with 95% O2 and
5% CO2, at 37°C. After 30 minutes of stabilization in
Ca2+-containing medium, selective antagonists were
added when indicated, and maintained for 15 minutes.
Aorta and tail artery segments were then stimulated or
not with NA for 5 minutes and then the tissues were
immediately frozen by liquid N2 immersion.
Protein extracts (50 lg) were loaded onto 10% Sodium
dodecyl sulphate-Polyacrylamide gels, and electrophoresed
proteins were transferred to polyvinyldiene fluoride
(PVDF) membranes 2 hours at 375 mA, using a liquid
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Mini Trans-Blot Electrophoretic Transfer Cell system
(Bio-Rad Laboratories, Inc., S. A. Madrid, Spain). Mem-
branes were blocked in albumin from bovine serum 3%
in phosphate-buffered saline (PBS) containing 0.1%
Tween 20 for 1 hour at room temperature with gentle
agitation. Membranes were incubated overnight at 4°C
with anti-phospho-p42/44 ERK MAPK (Thr202/Thr204)
and anti-p42/44 ERK MAPK (1:500; Cell Signaling Tech-
nology, Beverly, MA). Membranes were then washed three
times with PBS with 0.1% Tween 20, incubated with anti-
rabbit immunoglobulin G horseradish peroxidase-linked
whole antibody (1:2500; GE Healthcare, Buckinghamshire,
U.K.) for 45 minutes at room temperature and washed
extensively with phosphate buffered saline with tween
before chemiluminescent detection was performed using
the the ECLTM Prime Western Blotting Detection Reagents
(GE Healthcare, Buckinghamshire, U.K.). The image was
captured with the AutoChemi System (Ultra-Violet Prod-
ucts Bioimaging Systems, Cambridge, U.K.) and band
intensity was measured using LabWorks 4.6 Image acqui-
sition and Analysis (Ultra-Violet Products Bioimaging
Systems, Cambridge, U.K.).
Drugs and solutions
The following drugs were obtained from SIGMA (St.
Louis, MO): (-)-NA, prazosin, BMY 7378 (8-[2-[4-(2-
Methoxyphenyl)-1-piperazynil]-8-azaspiro [4,5]decane-
7,9-dione dihydrochloride) and 5-methylurapidil. Other
reagents were of analytical grade. All compounds were
dissolved in distilled water. The composition of Krebs
solution was (mmol/L) NaCl 118, KCl 4.75, CaCl2 1.8,
MgCl2 1.2, KH2PO4 1.2, NaHCO3 25, and glucose 11.
Ca2+-free solution had the same composition except that
CaCl2 was omitted and EDTA (0.1 mmol/L) was added.
The terminology for receptors employed is as recom-
mended in Alexander et al. (2011).
Results
NA exhibits higher potency but lower
efficacy in aorta than in tail artery
NA elicited a concentration-dependent contraction, ERK
1/2 phosphorylation, and [3H]-IPs accumulation in both
rat aorta and tail artery (Fig. 1). The potency (pEC50)
of NA was higher in aorta than in tail artery, for all
three measures; conversely, this increase in potency was
accompanied by an apparently lower efficacy in IPs for-
mation and ERK1/2 phosphorylation in aorta when
normalized for protein content (Fig. 1A and B). It is
not practicable to compare contractile efficacy between
different vessels.
CRC of NA were also performed in aortic and tail
artery rings from a1B-KO, a1D-KO, a1B/D-KO, or WT
mice and the results are shown in Figure 2. As in rat ves-
sels, in WT mice the pEC50 of NA was significantly higher
in aorta than in tail artery (8.28  0.02 and 7.23  0.05,
respectively, P < 0.001). Comparing a1D-KO with WT,
the pEC50 of NA was reduced in aorta and tail artery,
although the maximal response (Emax) was not different
(Fig. 2) in either case. No significant difference in
potency of NA was observed between aortic rings from
WT and a1B-KO mice although the Emax was signifi-
cantly reduced. In a1B/D-KO, a contractile response of
aorta was detectable only with the three highest concen-
trations of NA and was so small that the pEC50 of the
CRC could not be calculated (Fig. 2A).
NA-induced contraction exhibits a slower
time-course in aorta than in tail artery
The concentration of NA needed to obtain the maximal
response (1 lmol/L in aorta, 10 lmol/L in tail artery
from rat and WT mice) evoked a contraction with differ-
ent time-course profile in each vessel (Figs. 3 and 4).
In order to clarify the role that each a1-AR subtype
plays in the distinctive time-course of the adrenoceptor-
mediated response observed in each vessel, we analyzed
changes in this response in the presence of subtype selec-
tive a1-antagonists in rat vessels or in knockout mice ves-
sels (a1B-KO, a1D-KO, a1B/D-KO, or WT mice) with the
objective of isolating the response to each receptor sub-
type.
We produced responses to single concentrations of NA
(1 lmol/L in rat aorta and 10 lmol/L in tail artery) in
the presence and absence of two selective antagonists, 5-
methylurapidil, selective for a1A-ARs and BMY 7378
selective for a1D-AR (Koshimizu et al. 2002). The concen-
tration of each antagonist was of the same order as its
pA2 and/or pKB in each vessel (Gisbert et al. 2003a).
In rat aorta, the kinetic of the NA-induced contraction
was not affected by 5-methylurapidil (Fig. 3A), nor was
the recovery of the basal tone after removal of the agonist
(Fig. 3B). In the presence of BMY 7378 a slightly faster
contractile response was observed (Fig. 3C) followed by a
faster recovery of basal tone after washing the tissue. As
Figure 3D shows, without antagonist, 5 minutes after
agonist removal 50% of the maximal response to NA
remained. However, in the presence of BMY, 5 minutes
after NA removal the vascular tone was only 20% of the
maximal contraction, and reached the basal levels around
10 minutes versus 20 minutes in the absence of BMY
7378.
In aorta from a1D-KO mice, the contractile response
elicited by NA was faster than in WT and not sustained,
2013 | Vol. 1 | Iss. 1 | e00001
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with a slow decay after reaching its maximal response
(Fig. 3E). In a1B-KO and a1B/D-KO mice, NA-induced
contraction reached the maximal value more slowly than
the contraction observed in aorta from WT (Fig. 3E).
After removal of the agonist by washing, the return to the
baseline was markedly slower in aorta from a1B-KO or
WT mouse than in aorta from a1D-KO and a1B/D-KO
mouse (Fig. 3F).
In rat tail artery, no significant changes were observed
in the time-course profile of the NA-induced contraction
in presence of any drug (Fig. 4A–D). In tail artery from
the a1D-KO mouse the profile of the contractile response
was similar to WT (Fig. 4E). The return to the baseline
was only slightly slower in WT than in a1D-KO mouse
(Fig. 4F) confirming the minor role of the a1D subtype in
this vessel.
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Figure 1. Concentration–response curves of noradrenaline (NA) on (A) p-ERK signaling pathway determined by immunoblotting. A representative
immunoblot was also included, (B) inositol phosphates accumulation (IPs), (C) vascular tone expressed as force units (mN). Experiments were
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a1-adrenoceptors exhibit activity after
removal of the agonist in aorta but not in
tail artery
Previous evidence indicates that cells expressing a1D-ARs
exhibit elevated basal levels of calcium [32] and of pERK
(McCune et al. 2000; Chalothorn et al. 2002) which could
be decreased by a1-AR antagonists including the nonsub-
type-selective prazosin or the a1D-AR-selective BMY 7378.
In rat aorta, the basal level of pERK1/2 (in the absence of
an adrenoceptor-mediated stimulus) was not significantly
changed by BMY 7378 (1 lmol/L) or prazosin (1 lmol/
L). No changes in basal phosphorylation of ERK1/2 were
observed in rat tail artery incubated with 5-methylurapidil
(1 lmol/L) or prazosin (1 lmol/L) (Fig. 5, white bars).
As expected, NA induced an increase in the phosphoryla-
tion of ERK1/2 in both vessels, which was inhibited by
prazosin and BMY 7378 in aorta and by prazosin and 5-
methylurapidil in tail artery (Fig. 5, black bars).
The incubation with selective antagonists did not
change the basal IPs levels in rat aorta, nor in rat tail
artery (Fig. 6, white bars). Addition of NA (1 lmol/L in
aorta, 10 lmol/L in tail artery) induced a marked increase
in the IPs accumulation which was completely inhibited
by prazosin (1 lmol/L) and by BMY 7378 (1 lmol/L) or
5-methylurapidil (1 lmol/L) in aorta or tail artery,
respectively (Fig. 6, black bars).
Following the experimental procedure described in the
methods section, we had previously observed in aorta
but not in tail artery a population of active a1D-ARs
that increases IPs accumulation after removal of the ago-
nist (Gisbert et al. 2003b). The same results were
obtained in the present work. Figure 6 (gray bars) quan-
tifies the magnitude of the IPs accumulation in aorta
observed after agonist removal, and shows that incuba-
tion with prazosin (1 lmol/L) or BMY 7378 (1 lmol/L)
inhibits it. Different results were observed in tail artery.
No increase in IPs was observed after removal of the
agonist and incubation with prazosin (1 lmol/L) or 5-
methylurapidil (1 lmol/L) did not modify IPs levels
(Fig. 6, gray bars).
None of the antagonists assayed modified the basal
tone of the rat aorta or tail artery (Fig. 7, white bars)
and, as expected, addition of NA to the bath chamber
promoted a sustained increase in tone that was almost
completely inhibited in presence of prazosin or either
BMY 7378 or 5-methylurapidil (Fig. 7, black bars).
After careful removal of the agonist and following the
experimental procedure previously described, a sponta-
neous increase in the vascular tone was observed in
aorta but not in tail artery (Fig. 7, gray bars). Incuba-
tion with prazosin (1 lmol/L) or BMY 7378 (1 lmol/
L) inhibits this increase in tone observed after agonist
removal, as has been previously shown (Gisbert et al.
2000, 2003b).
In order to elucidate if an inadequate washing or tissue
peculiarity rather than a special activity of one a1-AR
subtype could explain the increase in tone observed after
NA removal, we performed the same experimental proce-
dure in vessels from knockout mice. Experiments in aorta
from WT and a1B-KO mice show a spontaneous increase
in tone after NA-removal similar to that found in rat
aorta. However, a similar increase in tone was not
observed in aorta from a1D-KO or a1D/1B-KO mice after
NA-removal (Fig. 8). The spontaneous increase in tone
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Figure 2. Contractile responses to cumulative concentrations of
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KO), and a1B/D-adrenoceptor knockout (a1B/D-KO) mice. Emax
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observed in WT mouse was completely inhibited by praz-
osin (1 lmol/L) and BMY 7378 (1 lmol/L), but not by
5-methylurapidil (1 lmol/L) (Fig. 8B).
Discussion and Conclusions
The major findings of the present study are that the a1D-
subtype is responsible of the greater contractile sensitivity,
slower time-course and postactivation contraction to an
adrenoceptor-mediated stimulus in conductance vessels.
This conclusion can be drawn from differences observed
in the contractile response to NA between a conductance
artery (aorta) and distributing artery (tail artery) in two
species, the receptor subtype being isolated pharmacologi-
cally in the rat and by receptor subtype knockout in the
mouse.
Conducting arteries respond to
adrenoceptor-mediated stimulus with
higher sensitivity than distributing vessels
Rat aorta exhibited a higher sensitivity for NA than tail
artery and this difference was observed independently of
the signaling pathway analyzed: IPs accumulation, ERK1/
2 phosphorylation, or contractile response. Interestingly
when a measure of maximal response representing
efficacy was calculated this was not greater in aorta so
a generally “larger” response signal per se is not
implicated.
It is well known that rat, mouse, and human aorta
express protein of the three a1-ARs subtypes but, in func-
tional terms, the vasoconstrictor role of a1D is predomi-
nant (Kenny et al. 1995; Hussain and Marshall 1997;
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Figure 3. Time-course of the contractile response to noradrenaline in aorta from rat or transgenic mice. The magnitude of the contraction was
determined at different times after addition of NA (1 lmol/L) to the bath chamber (A, C, and E) or after removal of the agonist (B, D, and F), in
absence (control) or presence of selective antagonists (5-methylurapidil 0.1 lmol/L and BMY7378 0.01 lmol/L) or in different mouse strains: wild
type (WT), a1D-adrenoceptor knockout (a1D-KO), a1B-adrenoceptor knockout (a1B-KO), and a1B/D-adrenoceptor knockout (a1B/D-KO). Values
represent mean  SEM of n = (3–6) experiments.
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Gisbert et al. 2000, 2002, 2003a; Yamamoto and Koike
2001; Hosoda et al. 2005), whereas in rat tail artery the
a1A-subtype is mainly implicated in adrenoceptor-medi-
ated contraction (Gisbert et al. 2003a; Martı et al. 2005;
Docherty 2010). Thus, the greater sensitivity to NA
observed in aorta could be attributed to the main func-
tional role played by a1D-AR in this vessel. This proposal
was based on previous reports showing a higher potency
of NA and adrenaline on cloned a1D-ARs expressed in
different cell lines (Theroux et al. 1996; Perez-Aso et al.
2013), as well as aorta and other conducting arteries
where the a1D subtype plays a main functional role (Daly
et al. 2002; Tanoue et al. 2002; Deighan et al. 2005;
Hosoda et al. 2005; Methven et al. 2009a,b).
However, in native tissues, changes in potency of the
agonists could be also explained by structural or cellular
characteristics of vessels independent of the a1 subtype
involved. The present results obtained with gene-targeted
mice confirmed the higher sensitivity of the native a1D
subtype to NA as responsible for the higher potency
exhibited by the agonist in aorta since, in the mouse
model lacking the a1D-AR (a1D-KO), the pEC50 of NA
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Figure 4. Time-course of the contractile response to NA in tail artery from rat or transgenic mice. The magnitude of the contraction was
determined at different times after addition of NA (1 lmol/L) to the bath chamber (A, C and E) or after removal of the agonist (B, D, and F), in
absence (control) or presence of selective antagonists (5-methylurapidil 0.01 lmol/L and BMY7378 0.1 lmol/L) or in different mouse strains: wild
type (WT), a1D-adrenoceptor knockout (a1D-KO), a1B -adrenoceptor knockout (a1B-KO), and a1B/D-adrenoceptor knockout (a1B/D-KO). Values
represent mean  SEM of n = (3–6) experiments.
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was significantly lower than that observed in aorta from
a1B-KO or WT mice; a1B/D-KO compared with a1B-KO
gave a similar result. Moreover, the much smaller differ-
ence in potency and efficacy of CRC to NA observed in
tail artery between a1D-KO and WT mice suggests a lesser
role for a1D-ARs in this vessel; an earlier study using a1B-
KO showed also a lesser role for a1B-AR in this artery
(Daly et al. 2002).
After removal of the adrenoceptor-
mediated stimulus, the contractile response
disappears more slowly in conducting than
in distributing arteries
Aorta from rat or mouse exhibits a distinctive time-
course in the contractile response to an adrenoceptor-
mediated stimulus. The time-course profile of this
response is characterized by a slow decay in the contrac-
tile tone when the agonist was removed. We have previ-
ously described a similar time-course in other conducting
vessels such as iliac and proximal mesenteric arteries,
where a1D-AR plays a functional role (Ziani et al. 2002).
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On the contrary, in distributing vessels such as tail
artery, or resistance vessels such as small mesenteric
branches, where the a1D-AR has not a predominant role,
and the a1A-AR is the main subtype involved, this slow
time-course is not observed, and a fast decay in the con-
tractile tone after agonist removal was observed (Ziani
et al. 2002). Therefore, we can attribute the slower time-
course profile to the presence of the a1D-subtype in a ves-
sel but also it could be due to structural differences
between arteries. The use of selective antagonists in rat
aorta as well as studies in vessels from mice lacking the
a1D-subtype confirms the involvement of this receptor in
the distinctive time-course observed in conducting vessels.
A selective antagonist of the a1D-ARs, BMY 7378, but
not the a1A selective antagonist 5-methylurapidil (Michel-
otti et al. 2000; Koshimizu et al. 2002), affects to a great
extent the recovery of basal tone after agonist removal.
This difference was even more evident in knockout mice.
In strains where the a1D-AR was not expressed (a1D-KO
and a1B/D-KO), the recovery of basal tone was almost
complete 5 minutes after agonist washing whereas it takes
up 30 minutes in WT and a1B-KO mice. In tail artery
from all strains, the decay in this maximal response to
NA was faster than in aorta from rats or WT mice, and
similar to aorta from a1D-KO and a1B/D-KO mouse.
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In conclusion, after removal of the agonist, a faster
decay in the contractile tone was observed in aorta from
a1D-KO and a1B/D-KO mice versus WT and a1B-KO, and
this time-course profile of the adrenoceptor-mediated
contraction is similar to that observed in distributing ves-
sels such as tail artery. Therefore, a consequence of a1D-
ARs activation in conducting vessels is a sustained con-
tractile response when the stimulus disappears.
The next question that arises was the possible involve-
ment of the constitutive activity of a1D-ARs in this sus-
tained response. It has been reported that cloned a1D-ARs
exhibit constitutive activity, evidenced by increased levels
of calcium (Garcıa-Sainz and Torres-Padilla 1999a) or
pERK1/2 (McCune et al. 2000) that were selectively inhib-
ited by prazosin or BMY 7378, acting as inverse agonists.
After incubation with prazosin or BMY 7378, no
change was registered in p-ERK1/2 IPs or contractile tone
in aorta, which suggests that constitutive activity observed
in cloned a1D-ARs is not so evident in native receptors
and has not a relevant impact on the signaling pathway
or in the vascular tone. Therefore, there is no evidence
for the presence of a population of constitutively active
a1D-AR, coupled to p-ERK signal with a modulator role
on the basal vascular tone in aorta.
Interestingly, after activation by NA and removal of the
agonist, the a1D-ARs continue actively coupled to the IP
pathway and, at the same time, we observed a temporary
increase in vascular tone when NA was no longer present in
the bath. The experiments performed in knockout mice con-
firmed this peculiarity of a1D-ARs as the increased tonewhich
appears after agonist removal was observed only in WT and
a1B-KOmouse, but not in a1D-KOor a1B/D-KOmice.
Recent evidences indicate that a1D-ARs are expressed as
a multiprotein complex at the plasma membrane (Lyssand
et al. 2008, 2010) interacting with the syntrophin family
through a PSD95/DlgA/Zo-1 (PDZ)-domain (Chen et al.
2006). Syntrophin isoforms play selective roles in the a1D-
AR/dystrophin-associated protein complex signalosome as
a-syntrophin increases a1D-AR binding site density while
b2-syntrophin enhances a1D-AR coupling to downstream
signaling effectors (Lyssand et al. 2011). In addition, this
signaling complex is not mimicked by the a1A or a1B-AR
subtypes which suggest that it could be involved in the
peculiar activity exhibited by the a1D subtype.
The characteristic behavior of the a1D-AR has been pre-
viously reported (Gisbert et al. 2000, 2003b; Ziani et al.
2002) as constitutive activity which manifests only after
agonist stimulation and removal. Thus, in native vascular
smooth muscle, the a1D-ARs remain constitutively active
after agonist activation, and maintain the adrenoceptor-
mediated response when the agonist is removed; finally,
a1D-ARs are internalized and the vessel recovers the basal
tone. However, this activity observed after removal of the
agonist could be also attributed to a prolonged binding of
NA to a1D-ARs which activates them for a while. As we
have discussed in previous papers, this explanation does
not hold (Gisbert et al. 2000, 2003b) but in any case, the
more interesting result is not related to the fact that the
activity showed by a1D-ARs after removal of the agonist
was “truly” or only “apparent” constitutive activity. The
more interesting question is the physiological conse-
quence of this activity which explains the slower decay
observed in the adrenoceptor-mediated response when
the agonist is removed.
Figure 9. Schematic picture showing that preponderance of the most sensitive a1D-AR subtype in noninnervated conductance arteries such as
aorta, allows responsiveness to physiological levels of circulating catecholamines. The activity showed by this subtype after agonist removal
sustains the contractile tone and prevents abrupt changes in vessel caliber when the stimulus fluctuates. In innervated distributing arteries, high
local concentrations of NA are required to activate the less sensitive subtype of a1A-adrenoceptors which elicit a response that is rapid but short
lived, allowing fine adjustment of the contractile tone by perivascular sympathetic nerves.
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In fact, aortas from a1D-KO and a1B/D-KO mice, which
did not exhibit a spontaneous increase in tone after ago-
nist removal, had a time-course profile of recovery of the
basal tone faster than aorta from WT and a1B-KO mouse,
and similar to tail artery from any strain.
Physiological and therapeutic relevance of
a1D-ARs in conductance vessels
The present results show that, in response to a systemic
adrenoceptor-mediated stimulus, a poorly innervated con-
ductance vessel such as aorta, where a1D-AR is the main
functionally relevant subtype, responds with higher sensi-
tivity than a vessel where the a1A-AR subtype is domi-
nant, as occurs in tail artery. Thus, plasma levels of
catecholamines, which rarely exceed 10 nmol/L (Goldstein
et al. 2003) could induce a moderate adrenoceptor-medi-
ated response in conductance vessels. This contractile
response can be temporarily sustained when the agonist is
removed, due to the constitutive coupling of the a1D-sub-
type to IPs/contraction pathway after agonist removal,
and this mechanism would prevent abrupt changes in the
caliber of conductance arteries when the adrenoceptor-
mediated stimulus fluctuates.
However, the higher threshold for a1A-adrenoceptors
present in tail artery might take them out of the reach of
circulating levels of catecholamines. Thus the a1A-ARs
might require the high local concentrations produced
only by release of noradrenaline from perivascular nerves.
In this case, the response is fast and intense, and disap-
pears when the stimulus does. This mechanism would
permit the fine adjustment of the contractile tone of dis-
tributing vessels by the local nervous stimulus and conse-
quently the precise adjustment of blood flow. This
concept is consistent with the hypothesis of Stassen et al.
(1998) that a1A-adrenoceptors are present in blood vessels
only when adrenergic nerves are present and might add
the further idea that a1A-ARs are activated physiologically
only or mainly by nerves (Daly et al. 2002).
The differential role exhibited by the a1D and the a1A
subtypes, present in conductance or distributing and
resistance vessels, respectively, opens new lines of phar-
macological research looking for the selective modulation
of a given subtype as a more vessel selective, accurate,
and safe strategy to control vascular tone.
In conclusion, as Figure 9 depicts, high sensitivity to
agonist and persistence of response after agonist removal
is a property of a1D-adrenoceptors. Therefore, the pre-
ponderance of this subtype in noninnervated conductance
arteries such as aorta allows responsiveness to circulating
catecholamines and prevents abrupt changes in vessel cali-
ber when the stimulus fluctuates. Conversely, in inner-
vated distributing arteries, high local concentrations of
NA are required to activate a1A-adrenoceptors for a
response that is rapid but short lived allowing fine adjust-
ment of the contractile tone by perivascular sympathetic
nerves.
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